Brand Intelligence Graph
Company Overview
About Addition Therapeutics
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
Business Model & Competitive Advantage
The Gates Foundation's cornerstone role is the most significant signal: the foundation does not invest in biotechnology for financial returns — it invests in technologies with potential to address health challenges at global scale, particularly in low- and middle-income countries. A $100 million backing from Gates at stealth exit validates that PRINT's platform has credibility beyond rare Western diseases, likely targeting conditions like infectious disease, anemia, or metabolic disorders where gene therapy could have massive population-level impact.
Competitive Landscape 2025–2026
The re-dosable nature of PRINT is its core clinical advantage: all existing AAV gene therapies are one-time treatments because the immune system mounts an antibody response that prevents re-dosing. PRINT's LNP delivery avoids viral capsid immunogenicity, theoretically enabling booster dosing as needed — a critical advantage for diseases where a single gene therapy dose may not provide lifetime correction.
Key Differentiators
Emerging Innovator
Addition Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Addition Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Addition Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Addition Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Addition Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →